Patents by Inventor Hideyuki Saya

Hideyuki Saya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11814651
    Abstract: Provided is an epithelial tissue stem cell derived from an adult, which lacks at least one tumor suppressor gene.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: November 14, 2023
    Assignee: FUJITA ACADEMY
    Inventors: Hideyuki Saya, Yoshimi Arima, Takashi Semba, Akiyoshi Kasuga
  • Publication number: 20230348573
    Abstract: An antibody against spike protein of SARS-CoV-2 is provided, the antibody having a specific heavy chain variable region and a specific light chain variable region, or a fragment of the antibody, the antibody or fragment thereof inhibiting the binding between the spike protein of SARS-CoV-2 and ACE2, the antibody or fragment thereof inhibiting SARS-CoV-2 infection; and a pharmaceutical composition including the antibody or fragment thereof and a pharmaceutically acceptable carrier, the pharmaceutical composition including two or more kinds of the antibody or fragment thereof.
    Type: Application
    Filed: September 24, 2021
    Publication date: November 2, 2023
    Applicants: KEIO UNIVERSITY, JAPAN as represented by DIRECTOR GENERAL of NATIONAL INSTITUTE OF INFECTIOUS DISEASES, RIKEN, SHIGA UNIVERSITY OF MEDICAL SCIENCE, THE UNIVERSITY OF TOKYO
    Inventors: Masaru TAKESHITA, Tsutomu TAKEUCHI, Katsuya SUZUKI, Hideyuki SAYA, Yoshimasa TAKAHASHI, Saya MORIYAMA, Hidehiro FUKUYAMA, Chieko OKAMURA, Mikako SHIROUZU, Takehisa MATSUMOTO, Katsuhiko KAMADA, Yasushi ITOH, Hirohito ISHIGAKI, Misako NAKAYAMA, Yoshinori KITAGAWA, Yoshihiro KAWAOKA
  • Patent number: 11518982
    Abstract: A method for producing a mesenchymal cell line derived from a vertebrate adipose tissue, and a mesenchymal cell line derived from a vertebrate adipose tissue produced by the method. Advantageously, a method for producing a mesenchymal cell line derived from a vertebrate adipose tissue is achieved more simply, in a shorter period of time, and more efficiently. Also, a mesenchymal cell line is derived from a vertebrate adipose tissue produced by the production method. The method for producing a mesenchymal cell line derived from a vertebrate adipose tissue comprises: (A) inducing differentiation of one or more cells selected from a stromal vascular fraction comprising a mesenchymal stem cell, an adipose progenitor cell, and a stromal cell of a vertebrate adipose tissue into a mature adipocyte; and (B) inducing dedifferentiation of the mature adipocyte obtained in step (A) to obtain a mesenchymal cell line derived from the vertebrate adipose tissue.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: December 6, 2022
    Assignee: AdipoSeeds, Inc.
    Inventors: Yumiko Matsubara, Yasuo Ikeda, Keiichi Tozawa, Hideyuki Saya, Hiroyuki Nobusue
  • Publication number: 20220347125
    Abstract: [Problem] To provide novel anti-tumor agents and combination drugs. [Means to solve] To provide an anti-tumor agent containing, as an active ingredient, a glutathione level reducer or a glutathione S-transferase inhibitor, the anti-tumor agent being adapted to be administered simultaneously with an effective amount of a compound (II); an anti-tumor agent including a compound (II) as an active ingredient, the anti-tumor agent being adapted to be administered simultaneously with an effective amount of a glutathione level reducer or a glutathione S-transferase inhibitor; or an anti-tumor agent containing, as active ingredients, a compound (II) and a glutathione level reducer or a glutathione S-transferase inhibitor, where R5 is a linear or branched C1-6 alkyl group, R6 is hydrogen or halogen, R7 is a linear or branched C1-6 alkyl group optionally substituted with a substituent, the substituent being hydroxy or phenyl, and R8 is hydrogen or halogen.
    Type: Application
    Filed: May 7, 2020
    Publication date: November 3, 2022
    Inventors: Hideyuki SAYA, Osamu NAGANO, Yuji OTSUKI
  • Patent number: 11400076
    Abstract: The object of the present invention is to provide a novel pharmaceutical for suppressing cancer stem cells. In the present invention, a mitochondria inhibitor comprising a 2-nitroimidazole derivative is applied to the cancer stem cell as an active ingredient.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: August 2, 2022
    Assignees: KEIO UNIVERSITY, Sun Pharma Japan Limited
    Inventors: Hideyuki Saya, Oltea Sampetrean, Naoyoshi Koike, Nobuo Kubota
  • Patent number: 11376266
    Abstract: The present invention is directed to provide antitumor agent including water-soluble sulfasalazine as an active ingredient. Antitumor agents were obtained with, as the water-soluble sulfasalazine, a PEG-modified sulfasalazine represented by the following formula: wherein an average value of n is 4 or larger and 1136 or smaller.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: July 5, 2022
    Assignees: Keio University, Tokyo Institute of Technology
    Inventors: Hideyuki Saya, Osamu Nagano, Kenji Tsuchihashi, Kentaro Suina, Nobuhiro Nishiyama, Hiroyasu Takemoto, Takahiro Nomoto, Makoto Matsui, Keishiro Tomoda, Naoki Yamada, Tsukasa Nishimori
  • Publication number: 20200316027
    Abstract: The object of the present invention is to provide a novel pharmaceutical for suppressing cancer stem cells. In the present invention, a mitochondria inhibitor comprising a 2-nitroimidazole derivative is applied to the cancer stem cell as an active ingredient.
    Type: Application
    Filed: October 2, 2018
    Publication date: October 8, 2020
    Applicant: KEIO UNIVERSITY
    Inventors: Hideyuki SAYA, Oltea SAMPETREAN, Naoyoshi KOIKE, Nobuo KUBOTA
  • Publication number: 20200261476
    Abstract: The present invention is directed to provide antitumor agent including water-soluble sulfasalazine as an active ingredient. Antitumor agents were obtained with, as the water-soluble sulfasalazine, a PEG-modified sulfasalazine represented by the following formula: wherein an average value of n is 4 or larger and 1136 or smaller.
    Type: Application
    Filed: January 5, 2017
    Publication date: August 20, 2020
    Applicants: KEIO UNIVERSITY, TOKYO INSTITUTE OF TECHNOLOGY, TOKYO INSTITUTE OF TECHNOLOGY
    Inventors: Hideyuki SAYA, Osamu NAGANO, Kenji TSUCHIHASHI, Kentaro SUINA, Nobuhiro NISHIYAMA, Hiroyasu TAKEMOTO, Takahiro NOMOTO, Makoto MATSUI, Keishiro TOMODA, Naoki YAMADA, Tsukasa NISHIMORI
  • Publication number: 20200190474
    Abstract: A method for producing a mesenchymal cell line derived from a vertebrate adipose tissue, and a mesenchymal cell line derived from a vertebrate adipose tissue produced by the method. Advantageously, a method for producing a mesenchymal cell line derived from a vertebrate adipose tissue is achieved more simply, in a shorter period of time, and more efficiently. Also, a mesenchymal cell line is derived from a vertebrate adipose tissue produced by the production method. The method for producing a mesenchymal cell line derived from a vertebrate adipose tissue comprises: (A) inducing differentiation of one or more cells selected from a stromal vascular fraction comprising a mesenchymal stem cell, an adipose progenitor cell, and a stromal cell of a vertebrate adipose tissue into a mature adipocyte; and (B) inducing dedifferentiation of the mature adipocyte obtained in step (A) to obtain a mesenchymal cell line derived from the vertebrate adipose tissue.
    Type: Application
    Filed: November 30, 2016
    Publication date: June 18, 2020
    Inventors: Yumiko MATSUBARA, Yasuo IKEDA, Keiichi TOZAWA, Hideyuki SAYA, Hiroyuki NOBUSUE
  • Publication number: 20200017834
    Abstract: Provided is an epithelial tissue stem cell derived from an adult, which lacks at least one tumor suppressor gene.
    Type: Application
    Filed: March 7, 2018
    Publication date: January 16, 2020
    Inventors: Hideyuki SAYA, Yoshimi ARIMA, Takashi SEMBA, Akiyoshi KASUGA
  • Publication number: 20180188258
    Abstract: A genetic marker is provided that can determine whether or not a cancer tissue contains a heterogeneous cancer cell population, the genetic marker being selected from the group consisting of CALML3, BGN, CLCA2, CSTA, ALDH1A1, NGFR, S100A8, ELN, SNURF, and LGALS7.
    Type: Application
    Filed: June 30, 2016
    Publication date: July 5, 2018
    Applicant: Keio University
    Inventors: Hideyuki Saya, Yoshimi Arima, Takashi Semba
  • Patent number: 9814707
    Abstract: The present invention is directed to provide cancer stem cell proliferation inhibitors and inducers of intracellular accumulation of reactive oxygen species. To this end, provided are cancer stem cell proliferation inhibitors and inducers of intracellular accumulation of reactive oxygen species in a cancer stem cell each containing pimozide or sertindole as an active ingredient.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: November 14, 2017
    Assignee: Keio University
    Inventors: Hideyuki Saya, Osamu Nagano, Shogo Okazaki
  • Publication number: 20170105984
    Abstract: The present invention is directed to provide cancer stem cell proliferation inhibitors and inducers of intracellular accumulation of reactive oxygen species. To this end, provided are cancer stem cell proliferation inhibitors and inducers of intracellular accumulation of reactive oxygen species in a cancer stem cell each containing pimozide or sertindole as an active ingredient.
    Type: Application
    Filed: January 23, 2015
    Publication date: April 20, 2017
    Inventors: Hideyuki SAYA, Osamu NAGANO, Shogo OKAZAKI
  • Patent number: 9592213
    Abstract: Disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof. Specifically disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof, which comprises tranilast as an active ingredient thereof.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: March 14, 2017
    Assignees: National University Corporation Kumamoto University, Keio University, Link Genomis, Inc.
    Inventors: Hidetaka Katabuchi, Ritsuo Honda, Hideyuki Saya, Yoshimi Arima, Shinichiro Niwa, Yasutaka Makino
  • Publication number: 20120157535
    Abstract: Disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof. Specifically disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof, which comprises tranilast as an active ingredient thereof.
    Type: Application
    Filed: June 17, 2010
    Publication date: June 21, 2012
    Inventors: Hidetaka Katabuchi, Ritsuo Honda, Hideyuki Saya, Yoshimi Arima, Shinichiro Niwa, Yasutaka Makino
  • Patent number: 6022690
    Abstract: The present invention enables detection, and isolation of DNP, specific to leishmanias, and identification of the sequence thereof.Accordingly, a leishmania protozoan can be precisely detected. The present invention can be applied to a diagnosis reagent, diagnosis kit, and the like for diagnosing infection with a leishmania protozoan. Furthermore, brazil type leishmanias and mexico type leishmania can be differentiated, whereby the present invention can be applied to development of a remedy after the diagnosis of the leishmania infection. The present invention can be applied also to development of a reagent, a diagnosis kit, and the like for large-group examination for examining quickly and simply a large number of samples at a time in leishmaniasis propagating area.
    Type: Grant
    Filed: January 7, 1998
    Date of Patent: February 8, 2000
    Assignee: Sumitomo Electric Industries, Ltd.
    Inventors: Hideyuki Saya, Tatsuyuki Mimori, Jiichiro Sasaki, Motomi Nakata